Literature DB >> 26556007

Conjunctival Primary Acquired Melanosis: Is It Time for a New Terminology?

Frederick A Jakobiec1.   

Abstract

PURPOSE: To review the diagnostic categories of a group of conditions referred to as "primary acquired melanosis."
DESIGN: Literature review on the subject and proposal of an alternative diagnostic schema with histopathologic and immunohistochemical illustrations.
METHODS: Standard hematoxylin-eosin-stained sections and immunohistochemical stains for MART-1, HMB-45, microphthalmia-associated transcription factor (MiTF), and Ki-67 for calculating the proliferation index are illustrated.
RESULTS: "Melanosis" is an inadequate and misleading term because it does not distinguish between conjunctival intraepithelial melanin overproduction ("hyperpigmentation") and intraepithelial melanocytic proliferation. It is recommended that "intraepithelial melanocytic proliferation" be adopted for histopathologic diagnosis. Atypical proliferations are characterized either by bloated dendritic melanocytes with enlarged cell components (dendrites, cell bodies, and nuclei) or by epithelioid melanocytes without dendrites. Atypical polygonal or epithelioid pagetoid cells may reach higher levels of the epithelium beyond the basal layer. Immunohistochemistry defines the degree of melanocytic proliferation or the cellular shape (dendritic or nondendritic) (MART-1, HMB-45) or identifies the melanocytic nuclei (MiTF). Intraepithelial melanocytic proliferation without atypia represents increased numbers of normal-appearing dendritic melanocytes (hyperplasia or early neoplasia) that generally remain confined to the basal/basement membrane region. Intraepithelial nonproliferative melanocytic pigmentation signifies the usually small number of conjunctival basal dendritic melanocytes that synthesize increased amounts of melanin that is transferred to surrounding keratinocytes.
CONCLUSION: All pre- and postoperative biopsies of flat conjunctival melanocytic disorders should be evaluated immunohistochemically if there is any question regarding atypicality. This should lead to a clearer microscopic descriptive diagnosis that is predicated on an analysis of the participating cell types and their architectural patterns. This approach is conducive to a better appreciation of features indicating when to intervene therapeutically. An accurate early diagnosis should forestall unnecessary later surgery.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26556007     DOI: 10.1016/j.ajo.2015.11.003

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

Review 1.  Advances in the management of conjunctival melanoma.

Authors:  Gargi K Vora; Hakan Demirci; Brian Marr; Prithvi Mruthyunjaya
Journal:  Surv Ophthalmol       Date:  2016-06-16       Impact factor: 6.048

2.  Relationship between Conjunctival Intraepithelial Dendritic Melanocytes and Nevocytes.

Authors:  Frederick A Jakobiec; Paula Cortes Barrantes; Mary E Aronow
Journal:  Ocul Oncol Pathol       Date:  2020-02-14

3.  Clinical profile of melanocytic lesions of the ocular surface in a Hispanic population.

Authors:  Lucas A Garza-Garza; Eugenia M Ramos-Davila; Raul E Ruiz-Lozano; Kathia Gutierrez-Juarez; Julio C Hernandez-Camarena
Journal:  Int Ophthalmol       Date:  2022-04-19       Impact factor: 2.029

Review 4.  Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.

Authors:  Joel M Mor; Ludwig M Heindl
Journal:  Ocul Oncol Pathol       Date:  2016-12-08

Review 5.  Conjunctival Melanoma: Genetic and Epigenetic Insights of a Distinct Type of Melanoma.

Authors:  Ernesto Rossi; Giovanni Schinzari; Brigida Anna Maiorano; Monica Maria Pagliara; Alessandro Di Stefani; Emilio Bria; Ketty Peris; Maria Antonietta Blasi; Giampaolo Tortora
Journal:  Int J Mol Sci       Date:  2019-10-31       Impact factor: 5.923

6.  BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi.

Authors:  Jasmine H Francis; Hans E Grossniklaus; Larissa A Habib; Brian Marr; David H Abramson; Klaus J Busam
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-01-01       Impact factor: 4.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.